首页> 外国专利> CANCER THERAPEUTIC AGENT BY AGENT FOR CANCER-SPECIFIC INTRODUCTION OF PROSTACYCLIN RECEPTOR ANTAGONIST

CANCER THERAPEUTIC AGENT BY AGENT FOR CANCER-SPECIFIC INTRODUCTION OF PROSTACYCLIN RECEPTOR ANTAGONIST

机译：前列腺素受体拮抗剂的癌症特异性治疗代理商

页面导航

摘要
著录项
相似文献

摘要

PPROBLEM TO BE SOLVED: To elucidate involvement of EPC in cancer proliferation, and to provide a new cancer therapeutic agent preventing cancer cells from proliferating by suppressing the function and proliferation of EPC. PSOLUTION: An in vivo experiment revealed that the function of EPC in the bone marrow and the peripheral blood of mice transplanted with IP-deficient bone marrow cells is decreased, cancer cell proliferation in these mice is significantly suppressed as compared with mice transplanted with normal bone marrow cells, and the cancer proliferative activity can be restored by administering isolated normal EPC. It was further revealed that functional EPC is essential for cancer proliferation. Furthermore, it was found that the function and proliferation of EPC are suppressed by an IP antagonist. PCOPYRIGHT: (C)2011,JPO&INPIT

机译：

要解决的问题：阐明EPC参与癌症增殖，并提供一种新的癌症治疗剂，通过抑制EPC的功能和增殖来防止癌细胞增殖。

解决方案：一项体内实验显示，与IP缺陷小鼠相比，EPC在移植了IP缺陷骨髓细胞的小鼠的骨髓和外周血中的功能降低，这些小鼠的癌细胞增殖得到了显着抑制正常的骨髓细胞，可以通过施用分离的正常EPC恢复癌症的增殖活性。进一步揭示了功能性EPC对于癌症扩散至关重要。此外，发现IP拮抗剂抑制EPC的功能和增殖。

版权：（C）2011，日本特许厅＆INPIT 展开▼

著录项

公开/公告号JP2011102242A

专利类型
公开/公告日2011-05-26

原文格式PDF
申请/专利权人 ASAHIKAWA MEDICAL COLLEGE;
展开▼

申请/专利号JP20080057250
发明设计人 KAWABE JUNICHI;HASEBE NAOYUKI;OSAKI TAKANOBU;
展开▼

申请日2008-03-07
分类号A61K45;A61K31/4168;A61P43;A61P35;A61K9/127;
国家 JP
入库时间 2022-08-21 18:23:42

相似文献

专利
外文文献
中文文献